FDA pulls Covid antibody treatment because it's not effective against dominant omicron variants
December 01, 2022 at 16:32 PM EST
The FDA said bebtelovimab is no longer authorized for use because it is not expected to neutralize the omicron BQ.1 and BQ.1.1 subvariants.
